SDGR / Schrodinger, Inc. (SDGR) Reports Q4 Loss, Tops Revenue Estimates

Schrödinger, Inc. (NASDAQ:SDGR ) Q3 2023 Results Earnings Conference Call November 1, 2023 4:30 PM ET Company Participants Jaren Madden - Senior Vice more_horizontal

Schrödinger is a leading AI drug discovery company with a comprehensive platform used by researchers and scientists worldwide. The company's flagship more_horizontal

Schrodinger's stock has performed well this year due to AI hype and strength in its drug discovery business. While the company appears attractively va more_horizontal

Second-quarter revenue was down 9% year over year. Schrödinger increased revenue guidance for software revenue but decreased it for drug discovery. more_horizontal

Schrodinger, Inc. (SDGR) came out with a quarterly loss of $0.21 per share versus the Zacks Consensus Estimate of a loss of $0.43. This compares to lo more_horizontal

Goldman Sachs recently asserted “that AI adoption could boost productivity growth by 1.5 percentage points per year over a 10-year period.” Th more_horizontal

Schrodinger, Inc. (SDGR) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate more_horizontal

A Deloitte report about artificial intelligence (AI) in the life sciences puts it bluntly. Big data is the new currency for biopharma firms. more_horizontal